Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Haematopoietic stem cells in cirrhosis - Authors' reply.

Newsome PN, Fox R, Forbes SJ.

Lancet Gastroenterol Hepatol. 2018 May;3(5):298-299. doi: 10.1016/S2468-1253(18)30035-9. Epub 2018 Apr 6. No abstract available.

PMID:
29644971
2.

Origin-Specific Adhesive Interactions of Mesenchymal Stem Cells with Platelets Influence Their Behavior After Infusion.

Sheriff L, Alanazi A, Ward LSC, Ward C, Munir H, Rayes J, Alassiri M, Watson SP, Newsome PN, Rainger GE, Kalia N, Frampton J, McGettrick HM, Nash GB.

Stem Cells. 2018 Feb 28. doi: 10.1002/stem.2811. [Epub ahead of print]

PMID:
29488279
3.

Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease.

Townsend SA, Edgar RG, Ellis PR, Kantas D, Newsome PN, Turner AM.

Aliment Pharmacol Ther. 2018 Apr;47(7):877-885. doi: 10.1111/apt.14537. Epub 2018 Feb 15. Review.

PMID:
29446109
4.

Mesenchymal stromal cell therapy for liver diseases.

Alfaifi M, Eom YW, Newsome PN, Baik SK.

J Hepatol. 2018 Feb 7. pii: S0168-8278(18)30080-1. doi: 10.1016/j.jhep.2018.01.030. [Epub ahead of print] Review.

PMID:
29425678
5.

CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease.

Parker R, Weston CJ, Miao Z, Corbett C, Armstrong MJ, Ertl L, Ebsworth K, Walters MJ, Baumart T, Newland D, McMahon J, Zhang P, Singh R, Campbell J, Newsome PN, Charo I, Schall TJ, Adams DH.

Am J Physiol Gastrointest Liver Physiol. 2018 Apr 1;314(4):G483-G493. doi: 10.1152/ajpgi.00213.2017. Epub 2018 Feb 8.

PMID:
29420066
6.

Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells.

de Witte SFH, Luk F, Sierra Parraga JM, Gargesha M, Merino A, Korevaar SS, Shankar AS, O'Flynn L, Elliman SJ, Roy D, Betjes MGH, Newsome PN, Baan CC, Hoogduijn MJ.

Stem Cells. 2018 Apr;36(4):602-615. doi: 10.1002/stem.2779. Epub 2018 Feb 1.

PMID:
29341339
7.

NAFLD in 2017: Novel insights into mechanisms of disease progression.

Khan RS, Newsome PN.

Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):71-72. doi: 10.1038/nrgastro.2017.181. Epub 2018 Jan 4. No abstract available.

PMID:
29300050
8.

Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease.

Eddowes PJ, McDonald N, Davies N, Semple SIK, Kendall TJ, Hodson J, Newsome PN, Flintham RB, Wesolowski R, Blake L, Duarte RV, Kelly CJ, Herlihy AH, Kelly MD, Olliff SP, Hübscher SG, Fallowfield JA, Hirschfield GM.

Aliment Pharmacol Ther. 2018 Mar;47(5):631-644. doi: 10.1111/apt.14469. Epub 2017 Dec 22.

PMID:
29271504
9.

Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial.

Newsome PN, Fox R, King AL, Barton D, Than NN, Moore J, Corbett C, Townsend S, Thomas J, Guo K, Hull D, Beard HA, Thompson J, Atkinson A, Bienek C, McGowan N, Guha N, Campbell J, Hollyman D, Stocken D, Yap C, Forbes SJ.

Lancet Gastroenterol Hepatol. 2018 Jan;3(1):25-36. doi: 10.1016/S2468-1253(17)30326-6. Epub 2017 Nov 7.

10.

Guidelines on the management of abnormal liver blood tests.

Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, Hall R, Harrower U, Hudson M, Langford A, Mackie A, Mitchell-Thain R, Sennett K, Sheron NC, Verne J, Walmsley M, Yeoman A.

Gut. 2018 Jan;67(1):6-19. doi: 10.1136/gutjnl-2017-314924. Epub 2017 Nov 9.

11.

Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey.

Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S, Newsome PN, Oben J, Tomlinson J, Tsochatzis E.

Frontline Gastroenterol. 2017 Oct;8(4):252-259. doi: 10.1136/flgastro-2017-100806. Epub 2017 Apr 28.

PMID:
29067150
12.

Editorial: optimising non-invasive screening for advanced liver fibrosis in NAFLD.

Khan RS, Newsome PN.

Aliment Pharmacol Ther. 2017 Nov;46(9):899-900. doi: 10.1111/apt.14267. No abstract available.

PMID:
29023886
13.

Editorial: liver transplantation in patients with non-alcoholic fatty liver disease and obesity.

Townsend SA, Newsome PN.

Aliment Pharmacol Ther. 2017 Aug;46(4):459-460. doi: 10.1111/apt.14179. No abstract available.

PMID:
28707791
14.

Review article: new treatments in non-alcoholic fatty liver disease.

Townsend SA, Newsome PN.

Aliment Pharmacol Ther. 2017 Sep;46(5):494-507. doi: 10.1111/apt.14210. Epub 2017 Jul 4. Review.

PMID:
28677333
15.

Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease.

de Witte SFH, Merino AM, Franquesa M, Strini T, van Zoggel JAA, Korevaar SS, Luk F, Gargesha M, O'Flynn L, Roy D, Elliman SJ, Newsome PN, Baan CC, Hoogduijn MJ.

Stem Cell Res Ther. 2017 Jun 8;8(1):140. doi: 10.1186/s13287-017-0590-6.

16.

Changes in human hepatic metabolism in steatosis and cirrhosis.

Schofield Z, Reed MA, Newsome PN, Adams DH, Günther UL, Lalor PF.

World J Gastroenterol. 2017 Apr 21;23(15):2685-2695. doi: 10.3748/wjg.v23.i15.2685.

17.

The Role of a Dedicated Non-Alcoholic Fatty Liver Disease Clinic in 2016.

Townsend SA, Newsome PN.

Dig Dis. 2017;35(4):371-376. doi: 10.1159/000456589. Epub 2017 May 3. Review.

PMID:
28468015
18.

Aging of bone marrow- and umbilical cord-derived mesenchymal stromal cells during expansion.

de Witte SFH, Lambert EE, Merino A, Strini T, Douben HJCW, O'Flynn L, Elliman SJ, de Klein AJEMM, Newsome PN, Baan CC, Hoogduijn MJ.

Cytotherapy. 2017 Jul;19(7):798-807. doi: 10.1016/j.jcyt.2017.03.071. Epub 2017 Apr 24.

PMID:
28462821
19.

Caution in Using Non-Invasive Scoring Systems in NAFLD Beyond Highly Selected Study Populations.

Armstrong MJ, Schmidt-Martin D, Rowe IA, Newsome PN.

Am J Gastroenterol. 2017 Apr;112(4):653-654. doi: 10.1038/ajg.2017.28. No abstract available.

PMID:
28381853
20.

Sphingosine-1-Phosphate Prevents Egress of Hematopoietic Stem Cells From Liver to Reduce Fibrosis.

King A, Houlihan DD, Kavanagh D, Haldar D, Luu N, Owen A, Suresh S, Than NN, Reynolds G, Penny J, Sumption H, Ramachandran P, Henderson NC, Kalia N, Frampton J, Adams DH, Newsome PN.

Gastroenterology. 2017 Jul;153(1):233-248.e16. doi: 10.1053/j.gastro.2017.03.022. Epub 2017 Mar 28.

21.

Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.

Li L, Zhang Q, Yang H, Zou Q, Lai C, Jiang F, Zhao P, Luo Z, Yang J, Chen Q, Wang Y, Newsome PN, Frampton J, Maxwell PH, Li W, Chen S, Wang D, Siu TS, Tam S, Tse HF, Qin B, Bao X, Esteban MA, Lai L.

J Biol Chem. 2017 Mar 17;292(11):4755-4763. doi: 10.1074/jbc.M116.764787. Epub 2017 Jan 4.

23.

Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.

Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, Manas D, Shah T, Newsome PN, Reeves H, Shetty S.

QJM. 2017 Feb 1;110(2):73-81. doi: 10.1093/qjmed/hcw151.

24.

Mesenchymal stromal cells and liver fibrosis: a complicated relationship.

Haldar D, Henderson NC, Hirschfield G, Newsome PN.

FASEB J. 2016 Dec;30(12):3905-3928. Epub 2016 Sep 6. Review.

PMID:
27601441
25.

Non-alcoholic fatty liver disease in 2016.

Townsend SA, Newsome PN.

Br Med Bull. 2016 Sep;119(1):143-56. doi: 10.1093/bmb/ldw031. Epub 2016 Aug 19. Review.

26.

AAV-mediated liver-directed gene therapy for Acute Intermittent Porphyria: It is safe but is it effective?

Brunetti-Pierri N, Newsome PN.

J Hepatol. 2016 Oct;65(4):666-667. doi: 10.1016/j.jhep.2016.07.006. Epub 2016 Jul 12. No abstract available.

PMID:
27422751
27.

Liver regeneration - mechanisms and models to clinical application.

Forbes SJ, Newsome PN.

Nat Rev Gastroenterol Hepatol. 2016 Aug;13(8):473-85. doi: 10.1038/nrgastro.2016.97. Epub 2016 Jun 29. Review.

PMID:
27353402
28.

Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply.

Newsome PN, Armstrong MJ, Gaunt P.

Lancet. 2016 Jun 11;387(10036):2379. doi: 10.1016/S0140-6736(16)30672-9. No abstract available.

PMID:
27312304
29.

Clinical effectiveness of cell therapies in patients with chronic liver disease and acute-on-chronic liver failure: a systematic review protocol.

Than NN, Tomlinson CL, Haldar D, King AL, Moore D, Newsome PN.

Syst Rev. 2016 Jun 14;5:100. doi: 10.1186/s13643-016-0277-6. Review.

30.

Identifying patients with nonalcoholic steatohepatitis that are nonresponders to therapy.

Armstrong MJ, Gaunt P, Newsome PN.

Hepatology. 2016 Dec;64(6):2265-2266. doi: 10.1002/hep.28672. Epub 2016 Jul 18. No abstract available.

PMID:
27287457
31.

Advanced non-alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alström syndrome.

Gathercole LL, Hazlehurst JM, Armstrong MJ, Crowley R, Boocock S, O'Reilly MW, Round M, Brown R, Bolton S, Cramb R, Newsome PN, Semple RK, Paisey R, Tomlinson JW, Geberhiwot T.

Liver Int. 2016 Nov;36(11):1704-1712. doi: 10.1111/liv.13163. Epub 2016 Jun 10.

PMID:
27178444
32.

Entering the GOLDEN Age for Therapies in NASH.

Newsome PN.

Gastroenterology. 2016 May;150(5):1073-1076. doi: 10.1053/j.gastro.2016.03.014. Epub 2016 Mar 24. No abstract available.

PMID:
27018488
33.

Non-alcoholic fatty liver disease and liver transplantation.

Khan RS, Newsome PN.

Metabolism. 2016 Aug;65(8):1208-23. doi: 10.1016/j.metabol.2016.02.013. Epub 2016 Mar 3. Review.

PMID:
26997540
34.

Murine Models of Acute Alcoholic Hepatitis and Their Relevance to Human Disease.

Wilkin RJ, Lalor PF, Parker R, Newsome PN.

Am J Pathol. 2016 Apr;186(4):748-60. doi: 10.1016/j.ajpath.2015.12.003. Epub 2016 Feb 1. Review.

PMID:
26835538
35.

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K; LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN.

Lancet. 2016 Feb 13;387(10019):679-90. doi: 10.1016/S0140-6736(15)00803-X. Epub 2015 Nov 20.

PMID:
26608256
36.

Mesenchymal stromal cells - Where art thou?

Vigneswara V, Newsome PN.

J Hepatol. 2015 Dec;63(6):1306-8. doi: 10.1016/j.jhep.2015.09.007. Epub 2015 Sep 25. No abstract available.

PMID:
26409218
37.

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.

Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, Nasiri M, Yu J, Gough SC, Newsome PN, Tomlinson JW.

J Hepatol. 2016 Feb;64(2):399-408. doi: 10.1016/j.jhep.2015.08.038. Epub 2015 Sep 21.

38.

Mesenchymal stromal cell therapy in liver disease: opportunities and lessons to be learnt?

Owen A, Newsome PN.

Am J Physiol Gastrointest Liver Physiol. 2015 Nov 15;309(10):G791-800. doi: 10.1152/ajpgi.00036.2015. Epub 2015 Aug 27. Review.

39.

Hepatocyte cell therapy in liver disease.

Bartlett DC, Newsome PN.

Expert Rev Gastroenterol Hepatol. 2015;9(10):1261-72. doi: 10.1586/17474124.2015.1073106. Epub 2015 Jul 27. Review.

PMID:
26212798
40.

Trials of obeticholic acid for non-alcoholic steatohepatitis.

Armstrong MJ, Newsome PN.

Lancet. 2015 Jul 4;386(9988):28. doi: 10.1016/S0140-6736(15)61199-0. No abstract available.

PMID:
26169862
41.

Pretreatment of Mesenchymal Stem Cells Manipulates Their Vasculoprotective Potential While Not Altering Their Homing Within the Injured Gut.

Kavanagh DP, Suresh S, Newsome PN, Frampton J, Kalia N.

Stem Cells. 2015 Sep;33(9):2785-97. doi: 10.1002/stem.2061. Epub 2015 Jun 29.

42.

CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism.

Wilhelm A, Aldridge V, Haldar D, Naylor AJ, Weston CJ, Hedegaard D, Garg A, Fear J, Reynolds GM, Croft AP, Henderson NC, Buckley CD, Newsome PN.

Gut. 2016 Jul;65(7):1175-85. doi: 10.1136/gutjnl-2014-308325. Epub 2015 Jun 15.

43.

Serum alkaline phosphatase in multidrug resistance 2 (Mdr2(-/-) ) knockout mice is strain specific.

Trivedi PJ, Weston CJ, Webb GJ, Newsome PN, Hirschfield GM, Adams DH.

Hepatology. 2016 Jan;63(1):346. doi: 10.1002/hep.27874. Epub 2015 Jun 26. No abstract available.

PMID:
25930031
44.

Non-alcoholic fatty liver disease: when to intervene and with what.

Than NN, Newsome PN.

Clin Med (Lond). 2015 Apr;15(2):186-90. doi: 10.7861/clinmedicine.15-2-186.

PMID:
25824073
45.
46.

Editorial: Treatment for NASH - helping the liver or helping the heart?

Armstrong MJ, Newsome PN.

Aliment Pharmacol Ther. 2015 Mar;41(5):487. doi: 10.1111/apt.13060. No abstract available.

47.

A concise review of non-alcoholic fatty liver disease.

Than NN, Newsome PN.

Atherosclerosis. 2015 Mar;239(1):192-202. doi: 10.1016/j.atherosclerosis.2015.01.001. Epub 2015 Jan 13. Review.

PMID:
25617860
48.

Generation of knockout rabbits using transcription activator-like effector nucleases.

Wang Y, Fan N, Song J, Zhong J, Guo X, Tian W, Zhang Q, Cui F, Li L, Newsome PN, Frampton J, Esteban MA, Lai L.

Cell Regen (Lond). 2014 Feb 5;3(1):3. doi: 10.1186/2045-9769-3-3. eCollection 2014.

49.

Dysregulated hepatic expression of glucose transporters in chronic disease: contribution of semicarbazide-sensitive amine oxidase to hepatic glucose uptake.

Karim S, Liaskou E, Fear J, Garg A, Reynolds G, Claridge L, Adams DH, Newsome PN, Lalor PF.

Am J Physiol Gastrointest Liver Physiol. 2014 Dec 15;307(12):G1180-90. doi: 10.1152/ajpgi.00377.2013. Epub 2014 Oct 23.

50.

NAFLD is underrecognized in the primary care setting: UK experience.

Armstrong MJ, Houlihan DD, Newsome PN.

Am J Gastroenterol. 2014 Sep;109(9):1500-1. doi: 10.1038/ajg.2014.207. No abstract available.

PMID:
25196882

Supplemental Content

Loading ...
Support Center